FDA OKs Cimzia for Active Ankylosing SpondylitisFDA OKs Cimzia for Active Ankylosing Spondylitis

UCB Pharma has received a complete response letter on their supplemental application for certolizumab for active axial spondyloarthritis. FDA Approvals
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news